QuantX Biosciences
Overview
At QuantX, we leverage the power of computation and modeling to accelerate the discovery of superior medicines for validated targets in immunology and inflammation.
Funding and backers
Total raised
$85M
1 round on record
Latest round
$85M
Series B · Feb 2026 · 9 mo ago
Team
1-10
employees, estimated range
Backers
1
OrbiMed
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 8
Raised a round Series B $85M · led by LAV · The National Law Review
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Feb 2026 | $85M | LAV lead, Sanofi Ventures lead | The National Law Review |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Congruence, Biotheryx
Similar startupsby what they do, their industry and backers
Stop Harmful Inflammation and Get Better. Treating Neurodegenerative and Inflammatory Diseases.
By unleashing the power of covalent chemistry, we can deliver superior small molecule medicines with enhanced therapeutic benefit.
Mirador Therapeutics is a clinical-stage precision medicine company developing therapies for immune-mediated inflammatory and fibrotic…
Cyrus Bio is a computationally-driven discovery company focused on naturally existing proteins that show the potential to be turned into…
Degrading proteins.Saving lives.. Biotheryx is advancing a portfolio of first-in-class protein degraders, with an initial focus on…
Closing the Translational Gap in Inflammation and Immunology drug discovery A.
Financials
Total raised
$85M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2026 | $85M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
QuantX Biosciences Closes Oversubscribed $85M Series B Financing
Round co-led by LAV and Sanofi Ventures PRINCETON, NJ and SHANGHAI, CHINA - QuantX Biosciences, Inc., a computationally driven drug discovery and developmen ...
Read more
Report
QuantX Biosciences Closes Oversubscribed $85M Series B Financing
Round co-led by LAV and Sanofi Ventures
Read more
Report